Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

Simeprevir is an NS3/4A protease inhibitor approved for the treatment of hepatitis C infection, as a component of combination therapy. Simeprevir is metabolized by the cytochrome P450 (CYP) system, primarily CYP3A, and is a substrate for several drug transporters, including the organic anion transpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouwerkerk-Mahadevan, Sivi, Snoeys, Jan, Peeters, Monika, Beumont-Mauviel, Maria, Simion, Alexandru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756048/
https://www.ncbi.nlm.nih.gov/pubmed/26353895
http://dx.doi.org/10.1007/s40262-015-0314-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756048/
https://www.ncbi.nlm.nih.gov/pubmed/26353895
http://dx.doi.org/10.1007/s40262-015-0314-y

Ejemplares similares